- The preparation of this type of vaccine is safe because staff handle synthetic glycan molecules that are not dangerous, unlike the traditional protocol that uses viruses grown in fermenters.
- Synthetic glycans are chemically pure and their molecular composition is characterized in such a way as to meet GMP (Good Manufacturing Practice) regulatory standards, which serve to ensure greater safety and therapeutic efficiency, while promoting the manufacture of the product in large quantities at low cost.
Glycovax Pharma’s goal is to rapidly develop a semi-synthetic vaccine to protect the population from the SARS-C-OoV-2 virus responsible for the COVID-19 pandemic.
Dr. Roy’s team has the expertise to create glycoconjugate vaccines. He contributed to the development of the first semi-synthetic vaccine against Haemophilus influenzae type B (Hib). This vaccine has been administered to more than 65 million children worldwide and has effectively protected them against the disease.
Glycovax Pharma has the expertise to now produce the immunogenic glycans of SARS-CoV-2 in sufficient quantities for the development of a safe and economical glycoconjugate vaccine.
A first prototype of a semi-synthetic anti-SARS-CoV-2 vaccine is currently in development. With appropriate resources, the Glycovax Pharma team will be able to assess rapidly the effectiveness of this vaccine and determine if it is able to destroy the virus responsible for the COVID-19.
Once the clinical trials will be successful, this vaccine can then be manufactured quickly and on a large scale.